CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 02877) ANNOUNCEMENT OF TURNOVER INFORMATION FOR THE THREE MONTHS ENDED 31 MARCH 2016The Company is pleased to announce its financial information of turnover, which has not been reviewed by its auditors, for the three months ended 31 March 2016.
The board of directors (the "Board") of China Shineway Pharmaceutical Group Limited (the "Company") is pleased to announce the preliminary financial information of turnover of the Company and its subsidiaries (together, the "Group") for the three months ended 31 March 2016 based on its management accounts which have not been reviewed by the auditors.
Total turnover of the Group, which has not been reviewed by the auditors, for the three months ended 31 March 2016 decreased by approximately 14.7% as compared with the same period of 2015 to approximately RMB466million, and in particular:
Turnover for the three months ended 31 March 2016 of injection products decreased by approximately 18.0% as compared to the same period of 2015 to approximately RMB250 million;
Turnover for the three months ended 31 March 2016 of soft capsule products decreased by approximately 18.3% as compared to the same period of 2015 to approximately RMB95 million;
Turnover for the three months ended 31 March 2016 of granule products decreased by approximately 7.0% as compared to the same period of 2015 to approximately RMB97 million; and
Products in other forms recorded turnover of approximately RMB24 million for the three months ended 31 March 2016.
In terms of product mix, injection products, soft capsule products and granule products accounted for approximately 53.6%, 20.4% and 20.8% of the total turnover respectively, all of which have not been reviewed by the auditors, for the three months of 2016.
Shareholders and investors are advised to exercise caution in dealing in the shares of the Company.By order of the Board
China Shineway Pharmaceutical Group Limited Li ZhenjiangChairman
Hong Kong, 3 May 2016
As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Ms. Xin Yunxia, Mr. Li Huimin, Ms. Lee Ching Ton Brandelyn, and Mr. Chen Zhong; and the independent non-executive Directors are Mr. Hung Randy King Kuen, Ms. Cheng Li and Mr. Sun Liutai.
China Shineway Pharmaceutical Group Ltd. issued this content on 03 May 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 03 May 2016 08:38:04 UTC. Original document available at http://shineway.todayir.com/attachment/2016050316320100002503913_en.pdf |
